2 results
Approved WMOCompleted
The objectives of this study are to compare the safety and efficacy of 2 annual cycles of intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta 1a (Rebif*) in patients with active relapsing-remitting multiple sclerosis (…
Approved WMOCompleted
With this proof-of-concept study, we will address i. differences in dopamine release in T2DM patients versus historical lean controls, ii. whether timed restoring of dopamine signalling improves dopamine release and iii. whether this reinstatement…